Sigilon Therapeutics, Inc. (NASDAQ:SGTX – Get Rating) shares were down 0.6% on Tuesday . The stock traded as low as $0.93 and last traded at $0.93. Approximately 28,516 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 429,872 shares. The stock had previously closed at $0.94.
Wall Street Analyst Weigh In
Separately, Canaccord Genuity Group started coverage on Sigilon Therapeutics in a report on Wednesday, January 18th. They issued a "buy" rating and a $6.00 price objective for the company.
Get Sigilon Therapeutics alerts:Sigilon Therapeutics Stock Down 0.6 %
The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.31. The firm has a market cap of $30.20 million, a PE ratio of -0.69 and a beta of 0.86. The stock has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $0.60.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in SGTX. Millennium Management LLC purchased a new position in Sigilon Therapeutics during the 2nd quarter valued at about $256,000. Renaissance Technologies LLC grew its holdings in Sigilon Therapeutics by 131.8% during the 1st quarter. Renaissance Technologies LLC now owns 275,600 shares of the company's stock valued at $405,000 after buying an additional 156,689 shares in the last quarter. State Street Corp grew its holdings in Sigilon Therapeutics by 26.7% during the 1st quarter. State Street Corp now owns 330,471 shares of the company's stock valued at $486,000 after buying an additional 69,662 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Sigilon Therapeutics by 22.3% during the 3rd quarter. Vanguard Group Inc. now owns 300,912 shares of the company's stock valued at $152,000 after buying an additional 54,770 shares in the last quarter. Hedge funds and other institutional investors own 52.20% of the company's stock.
About Sigilon Therapeutics
(Get Rating)
Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.
Featured Articles
- Get a free copy of the StockNews.com research report on Sigilon Therapeutics (SGTX)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.